Evercyte Partners with ATCC to Develop Immortalized Human Cell Lines

Press Release – Evercyte GmbH
Evercyte Partners with ATCC to Develop Immortalized Human Cell Lines

Evercyte Logo

Contact Supplier: Evercyte GmbH
Supplier Press Release: Evercyte Partners with ATCC to Develop Immortalized Human Cell Lines
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 699 10 709 401
Website: www.evercyte.com

DECEMBER 18, 2013

Evercyte Partners with ATCC to Develop Immortalized Human Cell Lines

Vienna, Austria: – Evercyte, the Austrian-based producer of standardized, relevant cell systems, today announced it had formed a strategic partnership with the leading global biological materials resource and standards organization ATCC to develop and distribute immortalized cell lines that retain key performance characteristics of primary cells.

Immortalized primary cell lines are needed to provide scientists with a sufficient supply of physiologically relevant cells for extended studies in biological, medical, pharmaceutical, cosmetic, and toxicological research.

The partnership brings together the expertise of both organizations. Evercyte systematically establishes and functionally characterizes immortalized human cell lines from specific tissues and donors. ATCC provides extensive cell manufacturing and testing capabilities to assure the cell lines are fully defined and meet quality standards. Together, the organizations are making these unique cell lines available to the scientific community through existing global distribution channels.

Dr. Johannes Grillari, co-founder and Chief Scientific Officer of Evercyte, commented: “Our core expertise is to systematically establish and characterize innovative, immortalized human cell cultures for cell based assays in pharmaceutical, chemical, and cosmetic industries as well as in ecotoxicology.”

Assured Quality
“With ATCC as a partner, high quality large-scale production of immortalized cell material is assured. Our mutual customers can develop standardized, relevant and reproducible cell based model systems and assays. In addition, ATCC’s world-wide distribution network is a perfect match for Evercyte, especially in regard to customers in academia,” Dr. Grillari added.

Sharon Challberg, Principal, Corporate Development at ATCC, commented: “At ATCC, we’ve set the standard for providing the largest and most diverse collection of authenticated biological materials to the scientific community since 1925. Our mission is to provide biological materials for the advancement and application of scientific knowledge. This strategic partnership with Evercyte expands our ability to do so through a series of unique immortalized cell lines.”

Dr. Chengkang Zhang, Ph.D., ATCC’s technical lead for the joint program, added: “A key success factor of this partnership is the strength of the technical teams at both ATCC and Evercyte, given the combined years of experience in cell line development, characterization, and manufacturing.”

About Evercyte
Evercyte GmbH is a spin-off company of the University of Natural Resources and Life Sciences, Vienna (BOKU-VIBT). It was founded to offer immortalized cells that retain their primary-like human cell characteristics for pharmaceutical R&D.

By developing immortalized cells and cell lines that retain their parental characteristics, Evercyte seeks to accelerate drug discovery and development. Evercyte produces and delivers single immortalized cell strains, including mesenchymal stem cells that can be differentiated to the cell type of interest; cell panels with cell strains derived from different tissues or from donors of various health statuses. As a service, it offers customer-tailored immortalized cell strain development as well as cell based assay development.

Recently Evercyte entered the market for induced pluripotent stem cells by establishing human urine as a fully non-invasive method to generate relevant cellular model systems. Systematically establishing and commercializing relevant cell model systems from donors of different genetic backgrounds, Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population.

About ATCC
ATCC serves and supports the scientific community with industry-standard products and holds the world’s largest and most diverse collection of human, animal and plant cell lines, molecular genomic tools, microorganisms and biological products.

ATCC is a non-profit biological recourse centre (BRC) dedicated to acquiring authenticating, producing, preserving, developing and distributing standard reference microorganisms, cell lines and other materials for life science research.

ATCC was founded in Chicago in 1925 after a scientific committee of scientists identified a need for a central collection of microorganisms to serve scientists worldwide. The organization moved to Georgetown University in Washington, DC in 1937 from where it began to diversify its holdings as its collections grew.

In 1998, ATCC moved to its modern 126,000 sq. ft. repository, laboratories and headquarters at Manassas VA.

Contact:
Evercyte GmbH
Birgit Marckhgott
Tel: +43 699 1816 2222
Email:office@evercyte.com

OR

ATCC
Renée Randall
Tel: +1 (703) 365 2773
Email:rrandall@atcc.org

For more information about Evercyte partners with ATCC to develop immortalized human cell lines, please contact Evercyte directly.

Comments are closed.